Drug Trial Radar · NCT07208773
A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jun 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
260
Planned (sponsor's estimate)
Start
Oct 29, 2025
Primary completion
Jan 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Akesobio
- First posted
- Oct 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was designed to evaluate the efficacy and safety of YL201 in combination with Ivonescimab (AK112) in subjects with solid tumor.
Conditions
- Advanced Solid Tumors
- Non Small Cell Lung Cancer
- Small Cell Lung Cancer
Interventions
YL201Drug
YL201 will be administered as IV infusion
IvonescimabDrug
Ivonescimab will be administered as IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of adverse events (AEs)Time frame: Approximately within 36 months
- Maximum tolerate dose(MTD)Time frame: Approximately within 36 months
- Recommended Dose for ExpansionTime frame: Approximately within 36 months
- Objective Response Rate (ORR)Time frame: Approximately within 36 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.